article · Suez Canal University Medical Journal
Background: SOX2 is a transcription factor involved in the self-renewal and pluripotency of embryonic stem cells (ESCs). It is involved in various cancer types and affects cancer cell physiology viainvolvement in complicated cell signaling and protein-protein interactions. im: Our work aimedto assess the expression patterns of SOX2 in prostatic adenocarcinoma in correlation with the histopathological findings to evaluate its role as a prognostic marker or possible therapeutic target. Materials and Methods: forty-eight specimens of prostatic adenocarcinoma were stained first H&E then immunohistochemically for SOX2 and scored by two histopathologists. Results: thirty-eight specimens showed positive nuclear expression of SOX2; with variable degrees. SOX2 expression showed a statistically significant association with different grade groups; with p-value = 0.025. There was no statistically significant association between its expression and the patient’s demographic data. Conclusion: Overexpression of SOX2 in Prostatic Adenocarcinoma could be an indicator of higher tumor grade and poor prognosis. It could be used as a prognostic biomarker for tumor aggressiveness.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21608/scumj.2024.343084
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.